ZLN005 Ppargc1a Activator for Neuroinflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as ALS, Alzheimer's, Parkinson's, Huntington's, and others are inadequate, as they do not effectively address the underlying neuroinflammation mediated by microglia, leading to progressive motor and cognitive dysfunction.
Innovation Solution
Administration of the Ppargc1a activator, 2-(4-tert-butylphenyl)-1H-benzimidazole, known as ZLN005, which penetrates the blood-brain barrier to activate the Ppargc1a pathway in microglia, thereby suppressing microglia-mediated inflammatory responses and improving motor and cognitive functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (riluzole, bone marrow transplantation) are administered to treat neurodegenerative diseases, then modest effects in improving quality of life and extending survival are achieved, but the diseases are not cured and dramatic benefit is not provided
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of microglia-mediated neuroinflammation using Ppargc1a activators. By focusing on this specific pathway rather than general symptomatic treatment, the invention aims to address the root cause of neurodegeneration, thereby improving both treatment effectiveness and survival outcomes compared to current therapies.
Solution Approach 2:
The invention changes the therapeutic parameter from symptomatic management to mechanism-targeted intervention. By administering Ppargc1a activators that modulate microglial metabolism and inflammatory responses, the treatment shifts from providing modest quality of life improvements to potentially altering disease progression and extending survival through targeted biological parameter modification.
2Object-affected harmful factors
If microglia-mediated neuroinflammation is not addressed, then current treatments can be administered with acceptable safety, but progressive motor and cognitive dysfunction continues unchecked
Solution Approach 1:
The patent introduces Ppargc1a activators as intermediary compounds that mediate between the administered drug and the microglial inflammatory pathway. These compounds selectively target microglial metabolism and inflammatory responses without requiring complex delivery systems or invasive procedures, thereby addressing neuroinflammation while maintaining treatment ease of administration.
3Reliability
If no targeted therapy addressing underlying neuroinflammation is provided, then treatment protocols remain simple, but motor and cognitive dysfunction progressively deteriorates
Solution Approach 1:
The patent segments the complex neurodegenerative disease process into its key pathological component: microglia-mediated neuroinflammation. By developing Ppargc1a activators that specifically target this segmented pathway, the invention achieves disease modification through a focused mechanism rather than requiring complex multi-component treatment protocols, thereby improving reliability without excessive complexity.
Data Source
AI summary
The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.